Please Wait.....

Report

Global Lymphedema Treatment Market

Market Report I 2025-07-01 I 350 Pages I Data Bridge Market Research

The global lymphedema treatment is expected to reach USD 2,306,839.14 thousand by 2032 from USD 1,051,087.59 thousand in 2024, growing at a CAGR of 10.6% in the forecast period of 2025 to 2032.
Market Segmentation:
Global Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy and Others), Type (Secondary Lymphedema and Primary Lymphedema), Affected Area (Lower Extremity, Upper Extremity and Genitalia), Age Group (Adult, Geriatric and Pediatric), Route of Administration (Oral, Injectable and Topical), End User (Hospital, Speciality Clinics, Ambulatory Surgical Centers and Others) Distribution Channel (Pharmacy, Stores, Direct Tender and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest Of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest Of Asia-Pacific, Brazil, Argentina, Peru, Rest Of South America, Saudi Arabia, South Africa, UAE, Egypt, Kuwait, Israel and Rest Of Middle East and Africa) -Industry Trends & Forecast To 2032

Overview of the Global Lymphedema treatment are:

Driver

- Rise in the number of lymphedema cases globally
Restrain

- Significant cost burden associated with lymphedema management
Opportunity

- Expanding opportunities for drug development and regulatory approvals
Market Players:

The key market players for global Lymphedema treatment are listed below:

- Tactile Medical (U.S.)
- Essity Aktiebolag (publ) (Sweden)
- 3M (U.S.)
- Cardinal Health (U.S.)
- Lohmann & Rauscher GmbH & Co. KG (Germany)
- PAUL HARTMANN AG (Germany)
- medi GmbH & Co. KG (Germany)
- ConvaTec Inc. (U.K.)
- Juzo (Germany)
- Smith + Nephew (U.K.)
- SIGVARIS GROUP (Switzerland)
- Sanyleg Srl (Italy)
- Avet Pharmaceuticals Inc. (U.S.)
- ThermoTek Inc. (U.S.)
- Huntleigh Healthcare Limited (U.K.)
- KOYA MEDICAL (U.S.)
- AIROS Medical, Inc. (U.S.)
- BIOCOMPRESSION SYSTEMS (U.S.)
- Mego Afek ltd. (Israel)
- SIGVARIS GROUP (Switzerland)
- Sanyleg Srl (Italy)
- Thusane (France)

TABLE OF CONTENTS
1 INTRODUCTION 50
1.1 OBJECTIVES OF THE STUDY 50
1.2 MARKET DEFINITION 50
1.3 OVERVIEW OF GLOBAL LYMPHEDEMA TREATMENT MARKET 50
1.4 LIMITATIONS 52
1.5 MARKETS COVERED 52
2 MARKET SEGMENTATION 55
2.1 MARKETS COVERED 55
2.2 GEOGRAPHICAL SCOPE 56
2.3 YEARS CONSIDERED FOR THE STUDY 57
2.4 CURRENCY AND PRICING 57
2.5 DBMR TRIPOD DATA VALIDATION MODEL 58
2.6 MULTIVARIATE MODELLING 61
2.7 PRODUCT TYPE LIFELINE CURVE 61
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 62
2.9 DBMR MARKET POSITION GRID 63
2.10 MARKET END USER COVERAGE GRID 64
2.11 VENDOR SHARE ANALYSIS 65
2.12 SECONDARY SOURCES 66
2.13 ASSUMPTIONS 66
3 EXECUTIVE SUMMARY 67
4 PREMIUM INSIGHTS 75
4.1 PORTER'S FIVE FORCES 77
4.2 PESTEL ANALYSIS 78
4.3 INDUSTRY INSIGHTS - 79
4.3.1 MICRO AND MACROECONOMIC FACTORS 79
4.3.2 PENETRATION AND GROWTH PROSPECT MAPPING 79
4.3.3 KEY PRICING STRATEGIES 79
4.3.4 ANALYSIS AND RECOMMENDATION 79
4.4 INNOVATION TRACKER & STRATEGIC ANALYSIS 81
4.4.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS 81
4.4.1.1 MERGERS & ACQUISITIONS 81
4.4.1.2 TECHNOLOGY COLLABORATIONS 81
4.4.2 NUMBER OF PRODUCTS IN DEVELOPMENT 81
4.4.3 STAGE OF DEVELOPMENT 82
4.4.4 TIMELINES & MILESTONES 82
4.4.5 INNOVATION STRATEGIES & METHODOLOGIES 82
4.4.6 RISK ASSESSMENT & MITIGATION 83
4.4.7 FUTURE OUTLOOK 83
4.5 PIPELINE ANALYSIS - GLOBAL LYMPHEDEMA TREATMENT MARKET 85
4.5.1 CLINICAL TRIALS AND PHASE ANALYSIS 85
4.5.2 DRUG THERAPY PIPELINE 85
4.5.3 PHASE III CANDIDATES 86
4.5.4 PHASE II CANDIDATES 86
4.5.5 PHASE I CANDIDATES 86
4.5.6 OTHERS (PRE-CLINICAL AND RESEARCH) 87
4.5.7 CONCLUSION 87
4.6 EPIDEMIOLOGY- 88
4.6.1 INCIDENCE OF LYMPHEDEMA (GLOBAL & BY GENDER) 88
4.6.2 INCIDENCE OF LYMPHEDEMA BY GENDER 88
4.6.3 TREATMENT RATE 88
4.6.4 MORTALITY RATE 88
4.6.5 DRUG ADHERENCE AND THERAPY SWITCH MODEL 89
4.6.6 PATIENT TREATMENT SUCCESS RATES 89
4.7 TARIFF 90
4.7.1 OVERVIEW 90
4.7.2 TARIFF STRUCTURES 90
4.7.2.1 GLOBAL VS. REGIONAL TARIFF STRUCTURES 90
4.7.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES, CMS PRICING MODELS 90
4.7.2.3 EUROPEAN UNION: CROSS-BORDER TARIFF REGULATIONS AND REIMBURSEMENT POLICIES 91
4.7.2.4 ASIA-PACIFIC: GOVERNMENT-IMPOSED TARIFFS ON IMPORTED MEDICAL PRODUCTS 91
4.7.2.5 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION 91
4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS 91
4.7.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS 91
4.7.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS 91
4.7.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS 92
4.7.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS 92
4.7.4.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 92
4.7.4.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE 92
4.7.4.3 TARIFFS AND THEIR ROLE IN MEDICAL TOURISM 92
4.7.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS 92
4.7.5.1 WTO REGULATIONS ON HEALTHCARE TARIFFS 92
4.7.5.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 92
4.7.5.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS 92
4.7.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 92
4.7.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 93
5 REGULATORY FRAMEWORK- 94
5.1 NORTH AMERICA 95
5.2 SOUTH AMERICA 96
5.3 EUROPE 97
5.4 ASIA-PACIFIC 98
5.5 MIDDLE EAST & AFRICA 99
6 MARKET OVERVIEW 100
6.1 DRIVERS 102
6.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES GLOBALLY 102
6.1.2 INCREASE IN THE PREVALENCE OF CANCERS 103
6.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES 103
6.1.4 AVAILABILITY AND ADVANCEMENT OF MULTIPLE THERAPEUTIC OPTIONS 104
6.2 RESTRAINTS 106
6.2.1 SIGNIFICANT COST BURDEN ASSOCIATED WITH LYMPHEDEMA MANAGEMENT 106
6.2.2 LACK OF AWARENESS ABOUT THE DISEASE 107
6.3 OPPORTUNITIES 108
6.3.1 EXPANDING OPPORTUNITIES FOR DRUG DEVELOPMENT AND REGULATORY APPROVALS 108
6.3.2 STRATEGIC COLLABORATIONS AND ALLIANCES AMONG INDUSTRY STAKEHOLDERS 108
6.4 CHALLENGES 109
6.4.1 ABSENCE OF A DEFINITIVE CURATIVE TREATMENT 109
6.4.2 RESTRICTIVE AND INCONSISTENT REIMBURSEMENT POLICIES 110
7 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE 111
7.1 OVERVIEW 112
7.2 COMPRESSION THERAPY 115
7.3 SURGERY 117
7.4 DRUG THERAPY 118
7.5 LASER THERAPY 119
7.6 OTHERS 120
8 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TYPE 121
8.1 OVERVIEW 122
8.2 SECONDARY LYMPHEDEMA 125
8.3 PRIMARY LYMPHEDEMA 126
?
9 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA 127
9.1 OVERVIEW 128
9.2 LOWER EXTREMITY 131
9.3 UPPER EXTREMITY 131
9.4 GENITALIA 132
10 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP 133
10.1 OVERVIEW 134
10.2 ADULT 137
10.3 GERIATRIC 137
10.4 PEDIATRIC 138
11 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 139
11.1 OVERVIEW 140
11.2 ORAL 143
11.3 INJECTABLE 143
11.4 TOPICAL 144
12 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY END USER 145
12.1 OVERVIEW 146
12.2 HOSPITAL 149
12.3 SPECIALTY CLINICS 149
12.4 AMBULATORY SURGICAL CENTERS 150
12.5 OTHERS 150
13 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 151
13.1 OVERVIEW 152
13.2 PHARMACY STORES 155
13.3 DIRECT TENDER 155
13.4 OTHERS 156
14 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY REGION 157
14.1 OVERVIEW 158
14.2 NORTH AMERICA 162
14.2.1 U.S. 168
14.2.2 CANADA 174
14.2.3 MEXICO 179
?
14.3 EUROPE 184
14.3.1 GERMANY 190
14.3.2 FRANCE 195
14.3.3 UNITED KINGDOM 201
14.3.4 ITALY 206
14.3.5 RUSSIA 211
14.3.6 SPAIN 216
14.3.7 TURKEY 221
14.3.8 NETHERLANDS 226
14.3.9 SWITZERLAND 231
14.3.10 BELGIUM 236
14.3.11 POLAND 241
14.3.12 AUSTRIA 246
14.3.13 HUNGARY 251
14.3.14 NORWAY 256
14.3.15 IRELAND 261
14.3.16 LITHUANIA 266
14.3.17 REST OF EUROPE 271
14.4 ASIA-PACIFIC 272
14.4.1 CHINA 278
14.4.2 JAPAN 283
14.4.3 INDIA 288
14.4.4 SOUTH KOREA 293
14.4.5 AUSTRALIA 298
14.4.6 INDONESIA 303
14.4.7 SINGAPORE 308
14.4.8 PHILIPPINES 313
14.4.9 THAILAND 318
14.4.10 MALAYSIA 323
14.4.11 VIETNAM 328
14.4.12 REST OF ASIA-PACIFIC 333
14.5 MIDDLE EAST AND AFRICA 334
14.5.1 SOUTH AFRICA 340
14.5.2 SAUDI ARABIA 345
14.5.3 EGYPT 350
14.5.4 U.A.E. 355
14.5.5 ISRAEL 360
14.5.6 KUWAIT 365
14.5.7 REST OF MIDDLE EAST AND AFRICA 370
?
14.6 SOUTH AMERICA 371
14.6.1 BRAZIL 377
14.6.2 ARGENTINA 382
14.6.3 PERU 387
14.6.4 REST OF SOUTH AMERICA 392
15 GLOBAL LYMPHEDEMA TREATMENT MARKET, COMPANY LANDSCAPE 393
15.1 COMPANY SHARE ANALYSIS: GLOBAL 393
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 394
15.3 COMPANY SHARE ANALYSIS: EUROPE 395
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 396
16 SWOT ANALYSIS 397
17 COMPANY PROFILE 398
17.1 TACTILE MEDICAL 398
17.1.1 COMPANY SNAPSHOT 398
17.1.2 REVENUE ANALYSIS 398
17.1.3 COMPANY SHARE ANALYSIS 399
17.1.4 PRODUCT PORTFOLIO 399
17.1.5 RECENT DEVELOPMENT 400
17.2 ESSITY AKTIEBOLAG (PUBL) 401
17.2.1 COMPANY SNAPSHOT 401
17.2.2 REVENUE ANALYSIS 401
17.2.3 COMPANY SHARE ANALYSIS 402
17.2.4 PRODUCT PORTFOLIO 402
17.2.5 RECENT DEVELOPMENT 403
17.3 3M 404
17.3.1 COMPANY SNAPSHOT 404
17.3.2 REVENUE ANALYSIS 404
17.3.3 COMPANY SHARE ANALYSIS 405
17.3.4 PRODUCT PORTFOLIO 405
17.3.5 RECENT DEVELOPMENTS 405
17.4 CARDINAL HEALTH 406
17.4.1 COMPANY SNAPSHOT 406
17.4.2 REVENUE ANALYSIS 406
17.4.3 COMPANY SHARE ANALYSIS 407
17.4.4 PRODUCT PORTFOLIO 407
17.4.5 RECENT DEVELOPMENT 408
?
17.5 LOHMANN & RAUSCHER GMBH & CO. KG 409
17.5.1 COMPANY SNAPSHOT 409
17.5.2 COMPANY SHARE ANALYSIS 409
17.5.3 PRODUCT PORTFOLIO 410
17.5.4 RECENT DEVELOPMENT 411
17.6 AIROS MEDICAL, INC. 412
17.6.1 COMPANY SNAPSHOT 412
17.6.2 PRODUCT PORTFOLIO 412
17.6.3 RECENT DEVELOPMENT 413
17.7 ARJO 414
17.7.1 COMPANY SNAPSHOT 414
17.7.2 REVENUE ANALYSIS 414
17.7.3 PRODUCT PORTFOLIO 415
17.7.4 RECENT DEVELOPMENTS 415
17.8 AVET PHARMACEUTICALS INC. 416
17.8.1 COMPANY SNAPSHOT 416
17.8.2 PRODUCT PORTFOLIO 416
17.8.3 RECENT DEVELOPMENT 416
17.9 BAUERFEIND 417
17.9.1 COMPANY SNAPSHOT 417
17.9.2 PRODUCT PORTFOLIO 417
17.9.3 RECENT DEVELOPMENTS 418
17.10 BIOCOMPRESSION SYSTEMS 419
17.10.1 COMPANY SNAPSHOT 419
17.10.2 PRODUCT PORTFOLIO 419
17.10.3 RECENT DEVELOPMENT 423
17.11 CONVATEC INC. 424
17.11.1 COMPANY SNAPSHOT 424
17.11.2 PRODUCT PORTFOLIO 424
17.11.3 RECENT DEVELOPMENT 425
17.12 ENOVIS CORPORATION 426
17.12.1 COMPANY SNAPSHOT 426
17.12.2 REVENUE ANALYSIS 426
17.12.3 PRODUCT PORTFOLIO 427
17.12.4 RECENT DEVELOPMENTS 427
17.13 HUNTLEIGH HEALTHCARE LIMITED 428
17.13.1 COMPANY SNAPSHOT 428
17.13.2 PRODUCT PORTFOLIO 428
17.13.3 RECENT DEVELOPMENT 429
?
17.14 IMPEDIMED LIMITED 430
17.14.1 COMPANY SNAPSHOT 430
17.14.2 REVENUE ANALYSIS 430
17.14.3 PRODUCT PORTFOLIO 431
17.14.4 RECENT DEVELOPMENT/NEWS 431
17.15 JODAS EXPOIM PVT. LTD. 432
17.15.1 COMPANY SNAPSHOT 432
17.15.2 PRODUCT PORTFOLIO 432
17.15.3 RECENT DEVELOPMENT 432
17.16 JUZO 433
17.16.1 COMPANY SNAPSHOT 433
17.16.2 PRODUCT PORTFOLIO 433
17.16.3 RECENT DEVELOPMENT 434
17.17 KOYA MEDICAL 435
17.17.1 COMPANY SNAPSHOT 435
17.17.2 PRODUCT PORTFOLIO 435
17.17.3 RECENT DEVELOPMENT 435
17.18 LLC BINNOPHARM GROUP 436
17.18.1 COMPANY SNAPSHOT 436
17.18.2 PRODUCT PORTFOLIO 436
17.18.3 RECENT DEVELOPMENT 436
17.19 MCKESSON MEDICAL-SURGICAL INC. 437
17.19.1 COMPANY SNAPSHOT 437
17.19.2 REVENUE ANALYSIS 438
17.19.3 PRODUCT PORTFOLIO 438
17.19.4 RECENT DEVELOPMENT 439
17.20 MEDI GMBH & CO. KG 440
17.20.1 COMPANY SNAPSHOT 440
17.20.2 PRODUCT PORTFOLIO 440
17.20.3 RECENT DEVELOPMENT 442
17.21 MEDTRONIC 443
17.21.1 COMPANY SNAPSHOT 443
17.21.2 REVENUE ANALYSIS 443
17.21.3 PRODUCT PORTFOLIO 444
17.21.4 RECENT DEVELOPMENTS 445
17.22 MEGO AFEK LTD 446
17.22.1 COMPANY SNAPSHOT 446
17.22.2 PRODUCT PORTFOLIO 446
17.22.3 RECENT DEVELOPMENT 448
?
17.23 PAUL HARTMANN AG 449
17.23.1 COMPANY SNAPSHOT 449
17.23.2 REVENUE ANALYSIS 449
17.23.3 PRODUCT PORTFOLIO 450
17.23.4 RECENT DEVELOPMENT 450
17.24 PERFORMANCE HEALTH 451
17.24.1 COMPANY SNAPSHOT 451
17.24.2 PRODUCT PORTFOLIO 451
17.24.3 RECENT DEVELOPMENTS 453
17.25 PURETECH HEALTH INC 454
17.25.1 COMPANY SNAPSHOT 454
17.25.2 PIPELINE PORTFOLIO 454
17.25.3 RECENT DEVELOPMENT 455
17.26 SANYLEG SRL A SOCIO UNICO 456
17.26.1 COMPANY SNAPSHOT 456
17.26.2 PRODUCT PORTFOLIO 456
17.26.3 RECENT DEVELOPMENT 457
17.27 SIGVARIS GROUP 458
17.27.1 COMPANY SNAPSHOT 458
17.27.2 PRODUCT PORTFOLIO 458
17.27.3 RECENT DEVELOPMENTS 460
17.28 SMITH+NEPHEW 461
17.28.1 COMPANY SNAPSHOT 461
17.28.2 REVENUE ANALYSIS 461
17.28.3 PRODUCT PORTFOLIO 462
17.28.4 RECENT DEVELOPMENT 462
17.29 THERMOTEK 463
17.29.1 COMPANY SNAPSHOT 463
17.29.2 PRODUCT PORTFOLIO 463
17.29.3 RECENT DEVELOPMENT 463
17.30 THUASNE 464
17.30.1 COMPANY SNAPSHOT 464
17.30.2 PRODUCT PORTFOLIO 464
17.30.3 RECENT DEVELOPMENT 464
17.31 VIATRIS INC. 465
17.31.1 COMPANY SNAPSHOT 465
17.31.2 REVENUE ANALYSIS 465
17.31.3 PRODUCT PORTFOLIO 466
17.31.4 RECENT DEVELOPMENT 466
?
17.32 WHITE SWAN PHARMACEUTICAL 467
17.32.1 COMPANY SNAPSHOT 467
17.32.2 PRODUCT PORTFOLIO 467
17.32.3 RECENT DEVELOPMENTS 468
18 QUESTIONNAIRE 469
19 RELATED REPORTS 473
?

Not Sure / Need Reassuring
- Confirm Content
  - Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
    
    Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
    
    Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
    
    Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
- Sample Pages
  - With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
    
    It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
    
    To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Check for Alternatives
  - Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
    
    To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
Prices / Formats / Delivery
- Prices
  - All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
    
    Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Discounts
  - As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
    
    Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
    
    To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Available Currencies
  - Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
    
    Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
    
    To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
- Licenses
  - License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Global Site License
  - The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
    
    It is important to note that this may exclude Parent Companies or Subsidiaries.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Formats
  - The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
    
    If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
- Delivery
  - Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
    
    Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
    
    If a delay in delivery is expected you will be informed about it immediately.
- Shipping Charges
  - As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
    
    If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
Ordering
- By Credit Card
  - We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
    
    Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
    
    For more information on PayU please visit: https://www.payu.pl/en/about-us
- By Money Transfer
  - If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
    
    With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
Security
- Website security
  - We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
    
    Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
- Credit Card Security
  - We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
    
    PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.